Anzeige
Mehr »
Login
Freitag, 17.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
1.119 Leser
Artikel bewerten:
(2)

Amgen Joins American Kidney Fund Corporate Membership Program at 'Champion' Level

Finanznachrichten News

ROCKVILLE, MD / ACCESSWIRE / June 24, 2020 / The American Kidney Fund (AKF) today announced that Amgen has joined its new corporate membership program as a Champion-level member.

AKF and Amgen have a long history of partnership in the fight against kidney disease. For more than three decades, Amgen has supported AKF and its programs, including the AKF Clinical Scientist in Nephrology research program, the AKF Calendar Kids Program for children living with kidney disease, and most recently as the lead underwriter of AKF's FIRST30 educational campaign for patients new to dialysis. Over the years Amgen has provided significant support for AKF's Disaster Relief Program which provides emergency grants to dialysis patients affected by natural disasters.

Amgen also funded a major survey AKF undertook of dialysis patients and renal professionals which provided insights into the obstacles patients face in adhering to their treatment regimens. AKF published a report in 2018, "Barriers to Treatment Adherence for Dialysis Patients," based on the results of the survey.

Amgen's corporate membership in AKF will help to fund AKF's broad range of programs and services that fight kidney disease on all fronts and help people live healthier lives. AKF directly touches the lives of more kidney patients than any other kidney nonprofit, working to advance kidney disease awareness, prevention, early detection, treatment and research. A top-rated charity, AKF spends 97 cents of each donated dollar on patients and programs, not overhead.

"We are pleased that Amgen has joined AKF as a Champion-level member, underscoring their commitment to improving the health of those who are living with kidney disease," said LaVarne A. Burton, AKF president and CEO. "Amgen has been a part of many of our important initiatives over the years and we welcome this additional support to fund our vital programs."

"Amgen Nephrology is proud and privileged to join the American Kidney Fund as a corporate member in its mission to fight kidney disease. Amgen is proud of its longstanding support and partnership with the American Kidney Fund and the ongoing support for better patient care," said Ned Endler, executive director, Amgen Nephrology.

AKF's new corporate membership program is open to institutional partners that support AKF's core mission of fighting kidney disease and helping people live healthier lives. It provides essential direct support that helps fund AKF's work fighting kidney disease on all fronts-from prevention through post-transplant living.

To learn more about AKF's corporate membership program, please contact Fiona Lawless, senior director of corporate engagement, at flawless@kidneyfund.org or 301.984.6635.

About Us

The American Kidney Fund (AKF) fights kidney disease on all fronts as the nation's leading kidney nonprofit. AKF works on behalf of the 37 million Americans living with kidney disease, and the millions more at risk, with an unmatched scope of programs that support people wherever they are in their fight against kidney disease-from prevention through transplant. With programs that address early detection, disease management, financial assistance, clinical research, innovation and advocacy, no kidney organization impacts more lives than AKF. AKF is one of the nation's top-rated nonprofits, investing 97 cents of every donated dollar in programs, and holds the highest 4-Star rating from Charity Navigator and the Platinum Seal of Transparency from GuideStar.

For more information, please visit KidneyFund.org, or connect with us on Facebook, Twitter, Instagram and LinkedIn.

Contacts

Alice Andors11921 Rockville Pike, Suite 300, Rockville, MD 20852
Senior Director of CommunicationsWork: 240-292-7053 Mobile: 703-609-6085
aandors@kidneyfund.orgKidneyFund.org


SOURCE: American Kidney Fund



View source version on accesswire.com:
https://www.accesswire.com/595090/Amgen-Joins-American-Kidney-Fund-Corporate-Membership-Program-at-Champion-Level

© 2020 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.